These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8161288)

  • 41. Depot fluphenazine decanoate and enanthate for schizophrenia.
    David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
    Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D
    J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluphenazine plasma levels, dosage, efficacy, and side effects.
    Levinson DF; Simpson GM; Lo ES; Cooper TB; Singh H; Yadalam K; Stephanos MJ
    Am J Psychiatry; 1995 May; 152(5):765-71. PubMed ID: 7726317
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics.
    Rifkin A; Quitkin F; Kane J; Klein DF; Ross D
    Biol Psychiatry; 1979 Jun; 14(3):499-508. PubMed ID: 224958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment.
    Levinson DF; Simpson GM; Singh H; Yadalam K; Jain A; Stephanos MJ; Silver P
    Arch Gen Psychiatry; 1990 Aug; 47(8):761-8. PubMed ID: 2378547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.
    Schooler NR; Keith SJ; Severe JB; Matthews SM; Bellack AS; Glick ID; Hargreaves WA; Kane JM; Ninan PT; Frances A; Jacobs M; Lieberman JA; Mance R; Simpson GM; Woerner MG
    Arch Gen Psychiatry; 1997 May; 54(5):453-63. PubMed ID: 9152099
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Very high dose fluphenazine decanoate: a controlled trial in chronic schizophrenia.
    McClelland HA; Farquharson RG; Leyburn P; Furness JA; Schiff AA
    Arch Gen Psychiatry; 1976 Dec; 33(12):1435-9. PubMed ID: 11760
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
    Walker CA
    Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
    McLaren S; Cookson JC; Silverstone T
    Int Clin Psychopharmacol; 1992 Nov; 7(2):67-72. PubMed ID: 1487623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
    Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High doses of fluphenazine enanthate in schizophrenia. A controlled study.
    Dencker SJ; Johansson R; Lundin L; Malm U
    Acta Psychiatr Scand; 1978 May; 57(5):405-14. PubMed ID: 354329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia.
    Kane JM; Davis JM; Schooler N; Marder S; Casey D; Brauzer B; Mintz J; Conley R
    Am J Psychiatry; 2002 Apr; 159(4):554-60. PubMed ID: 11925292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fluphenazine enanthate in the outpatient treatment of late paraphrenia.
    Raskind M; Alvarez C; Herlin S
    J Am Geriatr Soc; 1979 Oct; 27(10):459-63. PubMed ID: 469146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G; Coyle J; Tune L
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fluphenazine plasma levels and clinical response.
    Marder SR; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J; Midha KK
    Psychopharmacol Bull; 1990; 26(2):256-9. PubMed ID: 2236467
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and quantitative EEG changes at different dosage levels of fluphenazine treatment.
    Itil TM; Saletu B; Hsu W; Kiremitci N; Keskiner A
    Acta Psychiatr Scand; 1971; 47(4):440-51. PubMed ID: 4947806
    [No Abstract]   [Full Text] [Related]  

  • 60. Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities.
    Asarnow RF; Marder SR; Mintz J; Van Putten T; Zimmerman KE
    Arch Gen Psychiatry; 1988 Sep; 45(9):822-6. PubMed ID: 3046554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.